Переходьте в офлайн за допомогою програми Player FM !
Highlights in colorectal cancer at ASCO GI 2024
Manage episode 405344754 series 2424442
In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed’s discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.
The post Highlights in colorectal cancer at ASCO GI 2024 appeared first on VJOncology.
174 епізодів
Manage episode 405344754 series 2424442
In this week’s podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed’s discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.
The post Highlights in colorectal cancer at ASCO GI 2024 appeared first on VJOncology.
174 епізодів
Усі епізоди
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.